Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy
No Thumbnail Available
Date
2019-10
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Neprilysin inhibitors (NEPi) are assisting the renin-angiotensin system (RAS) inhibitors in halting diabetic cardiomyopathy (DCM). Away from conventional tactic, a recent report revealed the renoprotective potential of NEPi and angiotensin-converting enzyme (ACE2) activator combination therapy against diabetic nephropathy. However, this combination so far not evaluated against DCM, thus the present investigation aiming the same.
Description
Keywords
Pharmacy, Cardiomyopathy, Neprilysin inhibitors (NEPi), Angiotensin-converting enzyme (ACE2)